Sponsor: BioNTech Pharmaceuticals
Sponsor Study ID: BNT317-01/PM1086-A001
Study Title: A Phase I, First-in-human, Open-label, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BNT317 in Patients With Advanced Solid Tumors
CTO #: 104114
NCT Number: NCT06750185
Phase: I
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Bladder; Breast; Cervix Uteri; Colon; Esophagus; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, Skin; Ovary; Pancreas; Prostate; Rectum; Small Intestine
Study Objectives: To determine the safety profile, and tolerability of BNT317 in patients with advanced solid tumors. To determine the MTD or the RP2D of BNT317 in patients with advanced solid tumors.